There are reports of Guillain-Barré syndrome (GBS) and cranial neuropathies occurring
during or shortly after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

COVID-19 vaccine and Guillain-Barresyndrome : let’s not leap to associations Page 1 Funding
The Lathia Laboratory is supported by the National Institutes of Health (R01 NS0117104, R01 …

We report a case of Guillain-Barré syndrome (GBS) following the first dose of
Oxford/AstraZeneca COVID-19 vaccine with papilledema as atypical onset. As the COVID …

Since the first case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was
reported in Wuhan, China, in December 2019, Coronavirus-19 (COVID-19) has become a …

Although SARS‐CoV‐2 vaccines are very safe, we report 4 cases of the bifacial weakness
with paresthesias variant of Guillain–Barré syndrome (GBS) occurring within 3 weeks of …

Guillain-Barré syndrome (GBS) is the most common and severe acute paralytic neuropathy,
with about 100,000 people developing the disorder every year worldwide [1]. Up to two …

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
responsible for coronavirus disease 2019 (COVID-19) led to the death of thousands of …

A 70-year-old woman, receiving 7.5 mg prednisone as a maintenance therapy for
rheumatoid arthritis (RA), presented with a rapidly, bilateral weakness and tingling sensation …

In March 2020, the WHO declared COVID‐19 to be a global pandemic and since December
2020, millions of vaccines have been administered. To date, cases of Guillain‐Barré …

COVID‐19 vaccine causing Guillain‐Barre syndrome, a rare potential side effect - Matarneh -
2021 - Clinical Case Reports - Wiley Online Library Skip to Article Content Skip to Article …